VPHIF Stock - Valeo Pharma Inc.
Unlock GoAI Insights for VPHIF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $53.91M | $27.75M | $13.56M | $7.47M | $6.58M |
| Gross Profit | $13.08M | $6.28M | $3.96M | $1.38M | $1.40M |
| Gross Margin | 24.3% | 22.6% | 29.2% | 18.5% | 21.3% |
| Operating Income | $-17,228,000 | $-19,604,000 | $-12,817,000 | $-4,343,000 | $-3,545,000 |
| Net Income | $-27,808,000 | $-25,746,000 | $-14,233,000 | $-4,761,000 | $-3,615,000 |
| Net Margin | -51.6% | -92.8% | -105.0% | -63.7% | -55.0% |
| EPS | $-0.32 | $-0.32 | $-0.20 | $-0.08 | $-0.07 |
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.
Visit WebsiteEarnings History & Surprises
VPHIFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 10, 2025 | — | — | — | — |
Q2 2025 | Jun 11, 2025 | — | — | — | — |
Q1 2025 | Jan 31, 2025 | $-0.02 | — | — | — |
Q3 2024 | Sep 12, 2024 | $-0.04 | $-0.06 | -65.2% | ✗ MISS |
Q2 2024 | Jun 13, 2024 | $-0.04 | $-0.06 | -59.5% | ✗ MISS |
Q1 2024 | Mar 15, 2024 | $-0.06 | $-0.06 | -6.4% | ✗ MISS |
Q4 2023 | Oct 31, 2023 | — | $-0.07 | — | — |
Q3 2023 | Sep 14, 2023 | $-0.04 | $-0.05 | -20.5% | ✗ MISS |
Q2 2023 | Jun 14, 2023 | $-0.05 | $-0.06 | -10.1% | ✗ MISS |
Q1 2023 | Jan 30, 2023 | $-0.05 | $-0.13 | -160.0% | ✗ MISS |
Q4 2022 | Oct 31, 2022 | — | $-0.09 | — | — |
Q3 2022 | Sep 13, 2022 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q2 2022 | Jun 14, 2022 | $-0.06 | $-0.06 | 0.0% | = MET |
Q1 2022 | Mar 24, 2022 | $-0.04 | $-0.07 | -100.0% | ✗ MISS |
Q4 2021 | Oct 31, 2021 | — | $-0.08 | — | — |
Q3 2021 | Sep 22, 2021 | $-0.03 | $-0.04 | -33.3% | ✗ MISS |
Q2 2021 | Jun 29, 2021 | — | $-0.02 | — | — |
Q1 2021 | Feb 24, 2021 | — | $-0.02 | — | — |
Q4 2020 | Oct 31, 2020 | — | $-0.01 | — | — |
Q3 2020 | Sep 29, 2020 | — | $-0.02 | — | — |
Latest News
Frequently Asked Questions about VPHIF
What is VPHIF's current stock price?
What is the analyst price target for VPHIF?
What sector is Valeo Pharma Inc. in?
What is VPHIF's market cap?
Does VPHIF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VPHIF for comparison